Home >  News >  Industry >  Pharma News >  Supreme Court dismisses...

Supreme Court dismisses plea challenging disinvestment process of HLL Lifecare

The plea, while referring to HLL Lifecare's role in providing emergency relief, said the country cannot afford to privatise an entity like it at this crucial juncture when the vaccination drive is still going on.;

By - Ruchika Sharma
Published On 2023-05-25 08:00 GMT   |   Update On 2023-05-25 08:00 GMT

Supreme Court of India

Advertisement

New Delhi: The Supreme Court has dismissed a plea challenging the disinvestment process of HLL Lifecare Ltd., a Central Public Sector Enterprise (CPSE) under the Union health ministry, saying it was not inclined to entertain the petition which related to a "pure issue of policy". A bench of Chief Justice D Y Chandrachud and Justices P S Narasimha and J B Pardiwala was hearing a petition filed by NGO 'Sabka Sahyog Society'.

Advertisement
"The issue which has been raised in the petition under Article 32 of the Constitution, namely, the disinvestment decision of the government in respect of Hindustan Latex Limited is a pure issue of policy. We are not inclined to entertain the Petition under Article 32 which shall accordingly stand dismissed," the bench said.
Article 32 of the Constitution gives individuals the right to move the Supreme Court to seek justice when they feel they have been unduly deprived of their rights.
HLL Lifecare is involved in manufacturing and marketing a range of contraceptives, women's healthcare products, hospital supplies as well as other pharmaceutical products.
The petitioner had said HLL Lifecare was a nodal agency in the procurement of PPE kits throughout the COVID-19 pandemic and vaccines.
It said the role played by HLL Lifecare during the pandemic was noteworthy and the ministry had nominated it as the nodal agency for the procurement and supply of emergency medical items to fight COVID.
The plea, while referring to HLL Lifecare's role in providing emergency relief, said the country cannot afford to privatise an entity like it at this crucial juncture when the vaccination drive is still going on.
In March 2022, the government had said it has received multiple preliminary bids for the firm.
The Department of Investment and Public Asset Management (DIPAM) had invited preliminary bids for selling the government's 100 per cent stake in the health sector CPSE.
Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

USFDA approves expanded indication for Takeda Vonvendi for adults, children with Von Willebrand Disease

Roche receives EU CE mark for Contivue for neovascular age-related macular degeneration

SC Questions Effectiveness of UCPMP, Seeks Govt Clarification on Pharma Freebies

Dr Reddy's Labs API Mirfield facility gets 7 USFDA observations

CDSCO Panel Rejects Theon Pharma's Proposal for Empagliflozin, Linagliptin, Metformin FDC

Virchow Biotech Gets CDSCO Panel Nod for Semaglutide BE, Phase III Trials

Industry needs to come forward, take advantage of funds available for MedTech Sector: DoP Joint Secretary

USFDA inspection: Aurobindo Pharma receives 8 observations for Unit-XII